But what about the subject itself? The impending European patent package, having now been declared lawful by the Court of Justice of the European Union (CJEU) following two legal challenges by Spain [Cases C-146 and 147/13, noted by the IPKat here], is gradually metamorphosing from blueprint to reality. Arrangements are now being made for the training of judges, the provision of court facilities and the projecting of existing patenting and dispute resolution techniques on to a fresh canvas. This is a scenario in which the accumulated experience, knowledge and wisdom of the life science sector cannot be relied upon in the absence of rigorous double-checking against a new framework for patenting, new litigation rules and -- this is going to hurt the most -- a set of complex transitional provisions. Unsurprisingly, then, this year's programme features a mock trial before the Unified Patent Court with real live judges [readers may already be familiar with this weblog's serialised and ongoing account of Bristows' test-drive of the 17th Edition of the Draft UPC rules here, here, here and here] as well as sessions on whether to exercise the opt-out option and on the nuts and bolts of patent enforcement. At times of change and uncertainty, it's comforting to be able to share one's anxieties and pick up ideas in the company of one's life science peers and compatriots rather than have to rub shoulders for a couple of days with those who work in other disciplines and do not share one's commercial reflexes.
|Headache? No, just|
second medical use ...
A European focus comes naturally to this Kat, but he notes that the programme goes wider than that. China-watcher and a former occasional contributor to this weblog Tom Carver leads the session on enforcing pharma patents in that vast, imponderable jurisdiction. The United States is also on the menu and, in this Kat's view, the choicest morsel on the menu is a comparison of the position relating to personal medicine patents as between the US and Europe. This session is led by Emil Pot (General Counsel, Actogenix, Belgium) and Brian Coggio (Of Counsel, Fish & Richardson, United States), a combination that instantly brought to the mind of this blogger the classic Dr Seuss image on the right. Personalised medicine, incidentally, has proved to be a very live topic in the past twelve-month, as readers' responses to Suleman Ali's February 2015 blogpost on that topic demonstrate.
|Watching out for icebergs -- or ice cubes?*|
If you're booking for this event, some discounts are available to suitably designated souls. If you book online, or email C5's affable Nathan Denham here, quoting the organisers' VIP Katcode P15-999-KAT16, you can expect to enjoy the benefit of a handsome 15% reduction on the registration fee
* Cat illustration from Bailey Boat Cat. Adventures of a feline afloat, here